<DOC>
	<DOC>NCT00817635</DOC>
	<brief_summary>This study will assess the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in patients with resistant hypertension.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of hypertension with MSSBP â‰¥ 140 mmHg and &lt; 180 mmHg Stable on a threedrug regimen (including a diuretic) for at least 4 weeks for the treatment of resistant hypertension Male and female patients 18 to 75 years of age Exclusion criteria: Recent history of MI, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack Clinically significant ECG findings related to cardiac conduction defects Type 1 diabetes or uncontrolled type 2 diabetes (HbA1c &gt; 9%) Malignancies within the last 5 years (excluding basal cell skin cancer) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Blood Pressure</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Resistant Hypertension</keyword>
</DOC>